Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP1 | P22413 | 19/20 | 0.67 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25841313 | 0.89 | ENPP1 (0.57) | ENPP1 | |
| SCHEMBL24015442 | 0.84 | ENPP1 (0.67) | ENPP1 | |
| SCHEMBL31502050 | 0.84 | ENPP1 (0.67) | ENPP1 | |
| SCHEMBL20813411 | 0.82 | ENPP1 (0.78) | ENPP1PDE1B | |
| SCHEMBL27111165 | 0.82 | ENPP1 (0.70) | ENPP1PDE1B | |
| SCHEMBL20814057 | 0.82 | ENPP1 (0.76) | ENPP1 | |
| SCHEMBL31502045 | 0.82 | ENPP1 (0.76) | ENPP1 | |
| SCHEMBL20814064 | 0.80 | ENPP1 (1.00) | ENPP1 | |
| SCHEMBL29857914 | 0.80 | ENPP1 (1.00) | ENPP1 | |
| SCHEMBL20813410 | 0.79 | ENPP1 (1.00) | ENPP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250099493-A1 | PHOSPHONATES AS INHIBITORS OF ENPP1 AND CDNP | STINGRAY THERAPEUTICS INC (US) | 2025-03-27 | — | — | US | disclosed |
| US-20230277570-A1 | ENPP1 Inhibitors and Their Use for the Treatment of Cancer | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2023-09-07 | — | — | US | disclosed |
| US-11707471-B2 | ENPP1 inhibitors and their use for the treatment of cancer | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2023-07-25 | — | — | US | disclosed |
| US-11701371-B2 | ENPP1 inhibitors and their use for the treatment of cancer | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2023-07-18 | — | — | US | disclosed |
| US-20230190927-A1 | ENPP1 INHIBITORS AND METHODS OF MODULATING IMMUNE RESPONSE | CYANA THERAPEUTICS LLC | 2023-06-22 | — | — | US | disclosed |
| US-20230190927-A1 | ENPP1 INHIBITORS AND METHODS OF MODULATING IMMUNE RESPONSE | CYANA THERAPEUTICS LLC | 2023-06-22 | — | — | US | disclosed |
| WO-2023077083-A1 | ENPP1 INHIBITORS AS INHIBITORS OF METASTASIS | ANGARUS THERAPEUTICS, INC. (US) | 2023-05-04 | — | — | WO | disclosed |
| WO-2022125613-A1 | PHOSPHONATES AS INHIBITORS OF ENPP1 AND CDNP | Stingray Therapeutics, Inc. (US) | 2022-06-16 | — | — | WO | disclosed |
| US-20210369747-A1 | ENPP1 Inhibitors and Their Use for the Treatment of Cancer | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2021-12-02 | — | — | US | disclosed |
| WO-2021226136-A1 | ENPP1 INHIBITORS AND METHODS OF MODULATING IMMUNE RESPONSE | ANGARUS THERAPEUTICS, INC. (US) | 2021-11-11 | — | — | WO | disclosed |
| WO-2019051269-A1 | ENPP1 INHIBITORS AND THEIR USE FOR THE TREATMENT OF CANCER | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2019-03-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11701371-B2 | ENPP1 inhibitors and their use for the treatment of cancer | ENPP1, ENPP3, ENTPD1 | ENPP1 1/4885PDE1B 740/4885 |
| US-20250099493-A1 | PHOSPHONATES AS INHIBITORS OF ENPP1 AND CDNP | ENPP1, ENPP3, PPP1R1B | ENPP1 1/4885PDE1B 229/4885 |
| US-20210369747-A1 | ENPP1 Inhibitors and Their Use for the Treatment of Cancer | ENPP1, ENPP3, ENTPD1 | ENPP1 1/4885PDE1B 740/4885 |
| US-20230190927-A1 | ENPP1 INHIBITORS AND METHODS OF MODULATING IMMUNE RESPONSE | ENPP1, STING1, ENPP3 | ENPP1 1/4885PDE1B 143/4885 |
| US-11707471-B2 | ENPP1 inhibitors and their use for the treatment of cancer | ENPP1, ENPP3, ENTPD1 | ENPP1 1/4885PDE1B 740/4885 |
| US-20230277570-A1 | ENPP1 Inhibitors and Their Use for the Treatment of Cancer | ENPP1, ENPP3, ENTPD1 | ENPP1 1/4885PDE1B 740/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.